Home
Håvard Søiland's picture

Håvard Søiland

Professor
  • E-mailHavard.Soiland@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2019. Thyroidectomy Versus Medical Management for Euthyroid Patients With Hashimoto Disease and Persisting Symptoms: A Randomized Trial. Annals of Internal Medicine. 453-464.
  • 2019. Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study. BMC Cancer. 1-23.
  • 2019. Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients - a randomized trial. BMC Cancer. 1-22.
  • 2019. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • 2019. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study. Breast. 52-58.
  • 2018. Diet in women with breast cancer compared to healthy controls - What is the difference? European Journal of Oncology Nursing. 20-24.
  • 2017. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Research.
  • 2017. Our genes, our selves: hereditary breast cancer and biological citizenship in Norway. Medicine, Health care and Philosophy. 89-103.
  • 2017. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifentreated patients. PLOS ONE. 1-12.
  • 2016. Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls. Breast. 100-106.
  • 2016. Capturing the experience: Reflections of women with breast cancer engaged in an expressive writing intervention. Cancer Nursing. E51-E60.
  • 2015. The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 pages.
  • 2014. Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
  • 2014. Ekspressiv skriving som egenterapeutisk verktøy ett år etter brystkreftdiagnosen - resultater fra en beskrivende pilotstudie. Nordisk tidsskrift for helseforskning. 45-61.
  • 2013. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • 2012. Å ta beslutningen sammen med pasienten. Tidsskriftet sykepleien. 70-73.
  • 2012. Klasiske biomarkører vs, nye molkylærbiologiske tester i prognose og prediksjon ved ajuvant behandling av brystkreft. Kirurgen. 166-171.
  • 2011. The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer. Anticancer Research. 443-449.
  • 2011. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients. Breast Cancer Research and Treatment. 137-146.
  • 2011. In patients younger than age 55 years with lymph node–negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! Journal of Clinical Oncology. 852-858.
  • 2011. Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiology, Biomarkers and Prevention. 1937-1943.
  • 2011. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Modern Pathology. 502-511.
  • 2010. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Modern Pathology. 1567-1576.
  • 2009. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Research and Treatment. 39-45.
  • 2009. Patients with Clinical/Radiological Hyperplasia of Mammary Glands Show Pathological Presistence of Temperature of Skin Points. Anticancer Research. 4697-4702.
  • 2009. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cellular Oncology. 335-343.
  • 2009. Co-expression of estrogen receptor agr and Apolipoprotein D in node positive operable breast cancer - possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Acta Oncologica. 514-521.
  • 2009. Apolipoprotein D predicts adverse outcome in women a parts per thousand yen70 years with operable breast cancer. Breast Cancer Research and Treatment. 519-528.
  • 2008. Prognostic Relevance of Androgen Receptor Detection in Operable Breast Cancer. Journal of Surgical Oncology. 551-558.
  • 2008. Comparison of Apolipoprotein D determination methods in breast cancer. Anticancer Research. 1151-1160.
  • 2008. Androgen receptor determination in breast cancer - A comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. Applied immunohistochemistry & molecular morphology (Print). 362-370.
  • 2007. Resuscitative emergency thoracotomy in a Scandinavian trauma hospital - is it justified? Injury. 34-42.
  • 2007. Resuscitative emergency thoracotomy in a Scandinavian trauma hospital - is it justified? Injury.
  • 2007. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Modern Pathology. 1307-1315.
  • 2007. Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged > 55 years. Cellular Oncology. 25-35.
  • 2006. Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years. Cellular Oncology. 295-303.
  • 2006. Benign peritoneal cystic mesothelioma. World Journal of Surgery. 560-566.
  • 2005. Acute pancreatitis in a young girl with the Netherton syndrome. Journal of Pediatric Surgery. 69-72.
Reader opinion piece
  • 2013. Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
Doctoral dissertation
  • 2008. Apolipoprotein D and Androgen Receptor in Operable Breast Cancer.
Abstract
  • 2013. Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 pages.
  • 2010. In operable node negative breast cancer patients under 71 years, lymph vessel invasion has no additional prognostic value to PhosphoHistone-3 proliferative activity. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 250-250.
  • 2010. Comparing the prognostic value of proliferation markers Ki67, mitotic activity index, phosphohistone-3 and classical variables in breast cancer. Virchows Archiv. 170-170.
  • 2009. Use of Receiver Operating Characteristic (ROC) Analysis To Determine the Most Optimal Prognostic Threshold for Adjuvant! in Lymph Node Negative Breast Cancer Patients < 55 Years. Cancer Research. 704S-705S.
  • 2009. Mitotic Activity Index Identifies Both Over- and Undertreated Lymph Node Negative Breast Cancer Patients < 55 Year According to the Norwegian Treatment Guidelines. Cancer Research. 706S-706S.
  • 2007. Tissue microarray and whole sections in small sized study populations for ER-alpha, PR, HER-2 and AR in operable breast cancer: correlation and relevance for prognostication. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1314-1314.
  • 2007. Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age. Breast Cancer Research and Treatment. S60-S61.
  • 2007. Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. Breast Cancer Research and Treatment. S216-S216.
  • 2007. ARHI (DIRAS3) and proliferation in lymph node negative breast cancer. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 1318-1318.
Poster
  • 2018. A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • 2010. Mitotic Activity Index and Bone Marrow Micrometastases is a Strong Prognostic Combination in Breast Cancer Patients.
Academic literature review
  • 2015. The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients. 24243-24275.
  • 2009. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. 241-254.
  • 2007. Emerging concepts of apolipoprotein D with possible implications for breast cancer. 195-209.
  • 2006. Microsatellite instability in colorectal cancer. 395-406.

More information in national current research information system (CRIStin)